<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05010694</url>
  </required_header>
  <id_info>
    <org_study_id>GH35-CRS001</org_study_id>
    <nct_id>NCT05010694</nct_id>
  </id_info>
  <brief_title>Dose Finding Study of GH35 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Primary Antitumor Activity of GH35 in Patients With Advanced Solid Tumors With KRAS Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Genhouse Bio Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Genhouse Bio Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and tolerability of GH35 in patients with KRAS mutant advanced solid&#xD;
      tumors.&#xD;
&#xD;
      Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in&#xD;
      patients with KRAS mutant advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 27, 2021</start_date>
  <completion_date type="Anticipated">December 12, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 12, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities (DLT)</measure>
    <time_frame>24 Days</time_frame>
    <description>Number of participants with dose limiting toxicities (DLTs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the safety of GH35 in subjects</measure>
    <time_frame>30 Months</time_frame>
    <description>Number of participants with treatment-emergent adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the pharmacokinetics of GH35</measure>
    <time_frame>1 Month</time_frame>
    <description>Blood plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) as assessed by RECIST 1.1 criteria</measure>
    <time_frame>30 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) as assessed by RECIST 1.1 criteria</measure>
    <time_frame>30 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) as assessed by RECIST 1.1 criteria</measure>
    <time_frame>30 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) as assessed by RECIST 1.1 criteria</measure>
    <time_frame>30 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>AdvAdvanced Solid Tumors</condition>
  <condition>Kirsten Rat Sarcoma</condition>
  <arm_group>
    <arm_group_label>Monotherapy Dose Escalation.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with GH35 alone, conducted until disease progression, intolerance or end of study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GH35 Tablet</intervention_name>
    <description>GH35 for oral administration at doses of Dose A, Dose B, Dose C, Dose D, Dose E and Dose F.</description>
    <arm_group_label>Monotherapy Dose Escalation.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects greater than or equal to 18 years old.&#xD;
&#xD;
          2. Histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumor&#xD;
             with KRAS mutation identified.&#xD;
&#xD;
          3. Expected survival time â‰¥12 weeks.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          5. Must have at least one measureable lesion per Response Evaluation Criteria in Solid&#xD;
             Tumours (RECIST) version 1.1.&#xD;
&#xD;
          6. Have documented disease progression or intolerance after first-line treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Gastrointestinal (GI) tract disease causing the inability to take oral medication.&#xD;
&#xD;
          2. Previous accept with KRAS G12C inhibitor.&#xD;
&#xD;
          3. Uncontrollable general infection.&#xD;
&#xD;
          4. Serious cardiovascular disease.&#xD;
&#xD;
          5. Left ventricular ejection fraction (LVEF) &lt;50 %.&#xD;
&#xD;
          6. Known history of hypersensitivity to any of the excipients of GH35 tablets&#xD;
&#xD;
          7. Pregnant or nursing (lactating) women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baohui Han, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Chest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Project Manager</last_name>
    <phone>0512-86861608</phone>
    <email>zhouyiming@genhousebio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Tianshu Liu, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Baohui Han, Professor</last_name>
      <phone>+8621-222-00000</phone>
      <email>hanxkyy@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumors, KRAS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

